
jul pm et
summari diversifi health care product compani focus nutrit product
diagnost gener drug medic devic
nm price-to-earnings oper ep
risk assess reflect abbott oper
competit market exposur rise price
pressur global market howev compani
rel strong posit key health care product
categori prospect brighten on-going
launch new medic product expans
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
see sale inclus st jude
medic stj aler acquisit rise
organ basi
expect revenu grow
compris devic sale grow
high-singl digit diagnost sale
mid- high-singl digit pharmaceut
doubl digit nutrit
pharmaceut sale growth due
brand gener model emerg market
achiev double-digit growth
diagnost sale alin system
continu acceler europ
system roll
januari complet
acquisit stj stj leader
cardiac neuromodul medic devic
sale combin
enabl becom leader
firm aler sale
make world leader point-of-car
medic optic unit johnson johnson
ep estim use
effect tax rate
acquisit divestitur
posit enabl establish
market-lead posit sever categori
also view divers product offer
geograph presenc posit growth
expect broadli across product
geographi addit stj
aler reposit portfolio
diagnost devic
largest segment expect
pursu sizeabl acquisit
compani focus dividend growth
debt paydown april paid
debt expect pay
anoth expect would
bring leverag net debt-to-ebitda
modest encourag recent
product launch alin system
freestyl libr
user grow monthli pace
risk target price recommend
pressur significantli stronger dollar
weak execut new product launch
target base
peer ep estim
due robust pipelin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview oper four report segment establish
pharmaceut product brand gener diagnost product nutrit product
cardiovascular neuromodul product combin segment gener billion sale
dec come establish pharmaceut diagnost
nutrit medic devic primarili compris cardiovascular
neuromodul product divers oper larg result strateg acquisit made
year well intern research develop program abbott command
lead market posit mani product sell
establish pharmaceut segment product includ broad line brand gener
pharmaceut manufactur world-wide market sold outsid unit state emerg
market product gener sold directli wholesal distributor govern agenc
health care facil pharmaci independ retail abbott-own distribut center
public warehous depend market serv growth strategi busi
increas breadth product offer launch new improv formul regist
product across multipl geograph region competit segment gener health
care pharmaceut compani
diagnost product includ broad line diagnost system test manufactur market
sold world-wide princip product segment includ molecular diagnost system point care
system rapid diagnost system informat autom solut use laboratori core
laboratori system area immunoassay clinic chemistri hematolog transfus
next-gener famili core laboratori system brand alin product segment
subject competit technolog innov price conveni use servic instrument warranti
provis product perform laboratori effici long-term suppli contract product potenti
overal cost-effect product gain
nutrit product includ broad line pediatr adult nutrit product manufactur
market sold world-wide product includ variou form prepar infant formula
similac adult pediatr nutrit product ensur nutrit product use enter
feed jeviti nutrit brand zone perfect bar competit factor
price retail distribut avail product form signific aspect competit search
ingredi innov
cardiovascular neuromodul product includ broad line rhythm manag
electrophysiolog heart failur vascular structur heart devic treatment cardiovascular
diseas well neuromodul devic manag chronic pain movement
disord product segment subject competit technolog innov price
conveni use servic product perform long-term suppli contract product potenti
overal cost-effect product gain
also product blood glucos continu glucos monitor system
includ freestyl brand
impact major develop complet two major acquisit aler lead firm
point-of-car diagnost octob billion cash st jude medic stj leader
cardiac neuromodul devic januari billion total believ
combin stj enabl becom leader cardiovascular care
also complet sale abbott medic optic vision care busi johnson
johnson billion februari complet sale non-u develop market
specialti brand gener busi mylan nv billion
financi trend revenu grew year-over-year billion dec larg
acquisit aler stj compar oper basi sale increas
spent approxim billion revenu research develop
compar billion revenu revenu normal
ep grew year-over-year per share free cash flow determin cash flow
oper less capit expenditur increas billion billion
billion respect
chairman board
senior vice-president financ
execut vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
stop medicaid expans senat
fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
success elimin individu
mandat passag tcja
decemb see develop
neg health care equip
compani fewer insur patient
futur like lead fewer procedur
expect hospit largest
consum medic equip
advers impact could pressur
sale medic equip compani
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index year
date june health
increas composit index
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
addit sub-industri mani product
area histor
use non-elect procedur
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
expans acquisit speed
new product come market
increas recent year
success effort food drug
administr fda reduc approv
time medic devic time
see price pressur incess head wind
medic equip compani although
hospit saw boost cash tcja
tax cut job act think
hospit cautiou capit
budget amid on-going shift value-bas
care loom roll-off
medic devic tax sought rais
total billion year took
effect mani compani implement
cost optim measur respons
medic devic excis tax suspend
sinc begin
suspend till end compani
health care equip sub-industri stand
benefit medic devic tax repeal
develop
question opinion
recent republican administr
 difficulti attempt
repeal afford act
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target in-lin peer
ep estim ep vs ahead estim
sale st jude medic rose nutrit sale remain challeng
fall declin china infant formula see continu
challeng pend new regul diagnost rose strong
growth core laboratori point-of-car see diagnost growth driver
aler acquisit back track establish rose
medic devic rose /jeffrey loo cfa
et cfra keep hold opinion share abbott laboratori
aler inc alr nr agre lower merger price
acquir alr
firm drop lawsuit tri
termin origin deal alr encount sever advers event
includ govern subpoena relat oversea sale practic alr
delay file annual report due time revenu recognit one
alr subsidiari also lost medicar bill privileg
appeal compani expect deal complet /jeffrey
laboratori keep target in-lin
peer ep estim set ep ep
vs estim sale rose sale
largest unit nutrit fell challeng china see continu
throughout diagnost rose establish pharma medic
devic guid pro-forma sale growth inclus st jude
medic exclud pend sale abbott medic optic mid-singl
digit ep rang accret st
analyst research note compani news
laboratori rais target
above-p ep estim
robust organ growth opportun driven compani pipelin
ep vs higher estim rais
ep ep sale increas
organ billion organ basi sale grew
nutrit busi diagnost establish
pharmaceut medic devic given stronger-than-expect
organ growth quarter increas expect organ sale
growth rang year recent launch
freestyl libr continu glucos monitor maintain rapid pace growth
user per month achiev total user global
promis product includ alin diagnost system
mitraclip valv repair /kevin huang cfa
keep target above-p
next ep estim due robust pipelin
ep estim remain unchang respect
ep vs ep higher estim
pharmaceut medic devic total sale grew organ
line expect organ growth
diabet care busi grew driven recent
launch freestyl libr user global monthli growth
diabet care could import growth driver year come
addit cadenc new product launch continu invest
research develop million vs
persuad us continu see organ growth exce
growth experienc recent year /kevin huang
et cfra rais opinion share abbott laboratori
buy hold rais target
peer ep estim set
ep vs ahead estim sale aid
acquisit rose encourag broad-bas product
geograph growth medic devic establish pharmaceut
diagnost nutrit rebound grew
pediatr nutrit sale grew china follow soft regulatori
chang believ well posit continu broad-bas growth
rais target line peer
forward ep estim ep vs
line estim rais ep estim
sale aid st jude acquisit rose oper basi
nutrit sale rose oversea sale rose rebound
recent declin china sale improv sequenti diagnost sale rose
rose encourag broad-bas
see acceler diagnost follow aler deal /jeffrey loo
et cfra keep hold opinion share abbott laboratori
rais target in-line-with-p
forward ep rais ep estim
ep vs estim sale
inclus st jude medic rose compar basi nutrit
sale fell oversea rose overal diagnost rose
pharmaceut medic devic nutrit sale china
remain challeng pend regulatori chang see solid sale
devic believ st jude integr proceed well /jeffrey loo
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
